By Denise Myshko
Trametinib (Mekinist) monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study, according to David M. … Read more
By Jason M. Broderick
Adding veliparib to frontline induction chemotherapy increased complete and CA-125 responses compared with chemotherapy alone in patients with high-grade serous ovarian cancer, according to an exploratory analysis of the phase III VELIA trial.1
The 3-arm … Read more
By Neil Osterweil
FROM SGO 2020
Patients with gynecologic malignancies who consumed only water for 24 hours before and 24 hours after each chemotherapy cycle had fewer dose delays and reductions compared with patients who didn’t fast, results of a
By Pam Harrison
Uptake of neoadjuvant chemotherapy (NAC) for the treatment of advanced ovarian cancer has increased dramatically since 2006 in the United States, but importantly, the median survival has also continued to increase, new research shows.
These trends confirm … Read more
By Jason M. Broderick
The anti-DLL4/VEGF bispecific antibody navicixizumab showed promising clinical activity when used in combination with paclitaxel in heavily pretreated patients with platinum-resistant ovarian cancer, according to findings from a phase Ib study.
The data build on positive … Read more
By Gina Columbus
Frontline maintenance treatment with Vigil immunotherapy demonstrated an improvement in relapse-free survival (RFS) compared with placebo in patients with stage III/IV ovarian cancer, especially in those with BRCA1/2 wild-type disease, according to phase II results from the … Read more
By Susan Moench, PhD, PA-C
Preliminary assessments of secondary study endpoints of a phase 3 clinical trial evaluating maintenance therapy with niraparib, an inhibitor of poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP), compared with placebo in patients with newly diagnosed advanced ovarian … Read more
By Susan Moench, PhD, PA-C
An interim analysis of results of the first phase 3 clinical trial evaluating an immune checkpoint inhibitor either in combination with or following platinum-based chemotherapy compared with chemotherapy alone in patients with previously untreated advanced … Read more
By Jennifer Smith
A survey of gynecologic cancer survivors has revealed why some of these patients don’t participate in clinical trials.
By Susan Moench, PhD, PA-C
Results of a randomized clinical trial evaluating video-assisted genetic counseling followed by either formal genetic counseling or direct referral for genetic testing in women with ovarian/fallopian/peritoneal cancer receiving adjuvant therapy showed that a significantly higher … Read more
NEW YORK – Data from a Phase I study published last week in the Journal of Clinical Oncology showed that Bayer’s investigational compound anetumab ravtansine (BAY 94-9343), an antibody-drug conjugate comprising an anti-mesothelin antibody linked to maytansinoid DM4, was well … Read more
By Matthew Stenger
In a first-in-human phase I trial reported in the Journal of Clinical Oncology, Desai et al found that the RAF family kinase inhibitor lifirafenib produced responses in several solid tumor types in patients with BRAF or … Read more
Malignant ovarian cancer is insidious: Known and feared for vague and uncharacteristic symptoms that often mean the disease is discovered so late that on average only four out of six patients are still alive after five years. Researchers from Aarhus … Read more
By Jason M. Broderick
An independent panel determined that the investigational agent VB-111 (ofranergene obadenovec) met the interim prespecified efficacy criterion in the phase III OVAL study in patients with platinum-resistant ovarian cancer, and that the trial should continue without … Read more
By Nichole Tucker
GEN-1 immunotherapy demonstrated dose-dependent efficacy results in newly diagnosed patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (EOC) when treated in combination with the standard of care, according to results from the OVATION 2 … Read more
BOSTON – In patients with advanced ovarian cancer, a combination of drugs known as immune checkpoint inhibitors and PARP inhibitors can produce powerful remissions, clinical trials have shown, but up until now investigators haven’t been able to predict which patients … Read more
By Will Boggs MD
NEW YORK (Reuters Health) – Pathogenic variants in RAD51C and RAD51D are associated with an increased risk of ovarian and breast cancer, researchers report.
“RAD51C and RAD51D are included in cancer gene panels that are widely … Read more
CLEVELAND, Ohio (March 4, 2020)–Women who proactively have their ovaries removed to minimize their cancer risk may face a greater risk–premature death because of heart disease. That’s according to a new study that identifies an increased risk for women with … Read more
IMV says new results from its phase 2 trial of lead drug DPX-Survivac, designed to stimulate a T cell response in ovarian cancer, have set it on course for a registration trial.
The Canadian biotech revealed data from the 22-patient … Read more
By Cancer Research UK
A genetic study has found evidence to suggest that women who take statins in the long term could be less likely to develop ovarian cancer, according to new research funded by Cancer Research UK published today … Read more
